PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs

Journal of Pharmaceutical Sciences

Volumn 105, Issue 2, 2016, Pages 460-475

  Turecek, Peter L ^a   Bossard, Mary J ^b   Schoetens, Freddy ^c   Ivens, Inge A ^d  

^a Baxalta Innovations GmbH   (Austria)

^b NEKTAR THERAPEUTICS   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d BAYER CORPORATION   (United States)

Author keywords

biopharmaceuticals; PEG reagent; PEGylation; PEGylation chemistry; polyethylene glycol; toxicology

Indexed keywords

ASPARAGINASE MACROGOL; CARBOHYDRATE; CERTOLIZUMAB PEGOL; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DRUG; MACROGOL; PEGADEMASE; PEGAPTANIB; PEGFILGRASTIM; PEGINESATIDE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA1A; PEGLOTICASE; PEGVISOMANT; POLYETHYLENE; PROTEIN; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL VACUOLE; CHEMICAL MODIFICATION; CHEMISTRY; DRUG APPROVAL; DRUG SAFETY; HUMAN; MOLECULE; NONHUMAN; PEGYLATION; PHAGOCYTE; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FOLDING; PROTEIN STABILITY; SYSTEMATIC REVIEW (TOPIC); TOXICOLOGY; ADVERSE DRUG REACTION; ANIMAL; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PROCEDURES;

ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; PROTEIN STABILITY;

EID: 84964433411     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1016/j.xphs.2015.11.015     Document Type: Review

References (138)

1. M. Morpurgo, and F.M. Veronese Conjugates of peptides and proteins to polyethylene glycols Methods Mol Biol 283 2004 45 70
2. G. Pasut, A. Guiotto, and F.M. Veronese Protein, peptide and non-peptide drug PEGylation for therapeutic application Expert Opin Ther Patents 14 2004 859 894
3. M.J. Roberts, M.D. Bentley, and J.M. Harris Chemistry for peptide and protein PEGylation Adv Drug Deliv Rev 54 4 2002 459 476
4. J.M. Harris Introduction for biotechnical and biomedical applications of poly(ethylene glycol) J.M. Harris, Poly(ethylene glycol chemistry) Biotechnical and Biomedical Applications 1992 Plenum Press New York 1 14
5. S. Zalipsky Functionalized poly(ethylene glycol) for preparation of biologically relevant conjugates Bioconjug Chem 6 2 1995 150 165
6. S. Zalipsky, and J.M. Harris Introduction to Chemistry and Biological Applications of Poly(ethylene glycol) J.M. Harris, S. Zalipsky, Poly(ethylene glycol). Chemistry and Biological Applications 1997 ACS Symposium series Washington, DC 1 13
7. F.M. Veronese, E. Boccu, O. Schiavon, and et al. Anti-inflammatory and pharmacokinetic properties of superoxide dismutase derivatized with polyethylene glycol via active esters J Pharm Pharmacol 35 11 1983 757 758
8. G. Bonora, and S. Drioli Reactive PEGs for protein conjugation F.M. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Basel 33 45
9. S. Zalipsky, and C. Lee Use of functionalized poly(ethylene glycol)s for modification of polypeptides H. JM, Poly(ethylene Glycol) Chemistry Biotechnical and Biomedical Applications 1992 Plenum New York 347 370
10. R.B. Greenwald, Y.H. Choe, J. McGuire, and C.D. Conover Effective drug delivery by PEGylated drug conjugates Adv Drug Deliv Rev 55 2003 217 250
11. S. Zalipsky Chemistry of polyethylene glycol conjugates with biologically active molecules Adv Drug Deliv Rev 16 1995 157 182
12. G.E. Francis, C. Delgado, D. Fisher, F. Malik, and A.K. Agrawal Polyethylene glycol modification: relevance of improved methodology to tumour targeting J Drug Target 3 1996 321 340
13. F.M. Veronese, and G. Pasut PEGylation, successful approach to drug delivery Drug Discov Today 10 21 2005 1451 1458
14. G.T. Hermanson Discrete PEG Reagents. Bioconjugate Techniques 2nd ed 2008 Academic Press Elsevier New York 707 742
15. D. Bhadra, S. Bhadra, P. Jain, and N.K. Jain Pegnology: a review of PEG-ylated systems Die Pharmazie 57 1 2002 5 29
16. S. Jevsevar, M. Kunstelj, and V.G. Porekar PEGylation of therapeutic proteins Biotechnol J 5 1 2010 113 128
17. K. Knop, R. Hoogenboom, D. Fischer, and U.S. Schubert Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives Angew Chem Int Ed Engl 49 36 2010 6288 6308
18. G. Pasut, and F.M. Veronese State of the art in PEGylation: the great versatility achieved after forty years of research J Control Release 161 2 2012 461 472
19. S.S. Banerjee, N. Aher, R. Patil, and J. Khandare Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications J Drug Deliv 2012 2012 103973
20. D. Filpula, and H. Zhao Releasable PEGylation of proteins with customized linkers Adv Drug Deliv Rev 60 1 2008 29 49
21. I.A. Ivens, W. Achanzar, A. Baumann, and et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development Toxicol Pathol 43 7 2015 959 983
22. J.S. Kang, P.P. Deluca, and K.C. Lee Emerging PEGylated drugs Expert Opin Emerg Drugs 14 2 2009 363 380
23. R. Webster, E. Didier, P. Harris, and et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies Drug Metab Dispos 35 1 2007 9 16
24. I.A. Ivens, A. Baumann, T.A. McDonald, T.J. Humphries, L.A. Michaels, and P. Mathew PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers Haemophilia 19 1 2013 11 20
25. Bentley MD, Harris JM, Kozlowski A. 2002. Heterobifunctional poly(ethylene)glycol derivatives and methods for their preparation. US Pat. 6,448,369.
26. Harris JM, Kozlowski, A. 1997. Poly (ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications. US Pat. 5,672,662.
27. Y.R. Gokarn, M. McLean, and T.M. Laue Effect of PEGylation on protein hydrodynamics Mol Pharm 9 4 2012 762 773
28. C.J. Fee, and J.M. Van Alstine Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins Bioconjug Chem 15 6 2004 1304 1313
29. M.D. Bentley, M.J. Bossard, K. Burton, and T. Viegas Poly(ethylene) glycol conjugates of biopharmaceuticals in drug delivery J. Knäblein, Part VI: Advanced Application Routes for Biopharmaceuticals 2005 Wiley New York 1393 1418
30. V.L. Mendoza, and R.W. Vachet Probing protein structure by amino acid-specific covalent labeling and mass spectrometry Mass Spectrom Rev 28 5 2009 785 815
31. L. Banci, I. Bertini, P. Caliceti, L. Monsu Scolaro, O. Schiavon, and F.M. Veronese Spectroscopic characterization of polyethyleneglycol modified superoxide dismutase: 1H NMR studies on its Cu2Co2 derivative J Inorg Biochem 39 2 1990 149 159
32. F.M. Veronese, L. Sartore, O. Schiavon, and P. Caliceti A comparative study of enzymatic, structural, and pharmacokinetic properties of superoxide dismutase isolated from two sources and modified by monomethoxypolyethylene glycol using different methods of coupling Ann N Y Acad Sci 613 1990 468 474
33. G. Digilio, L. Barbero, C. Bracco, and et al. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2 J Am Chem Soc 125 12 2003 3458 3470
34. K.D. Hinds, and S.W. Kim Effects of PEG conjugation on insulin properties Adv Drug Deliv Rev 54 4 2002 505 530
35. F. Meng, B.N. Manjula, P.K. Smith, and S.A. Acharya PEGylation of human serum albumin: reaction of PEG-phenyl-isothiocyanate with protein Bioconjug Chem 19 7 2008 1352 1360
36. F.M. Veronese, A. Mero, F. Caboi, M. Sergi, C. Marongiu, and G. Pasut Site-specific pegylation of G-CSF by reversible denaturation Bioconjug Chem 18 6 2007 1824 1830
37. H.F. Gaertner, and A.J. Puigserver Increased activity and stability of poly(ethylene glycol)-modified trypsin Enzyme Microb Technol 14 2 1992 150 155
38. B. Treetharnmathurot, C. Ovartlarnporn, J. Wungsintaweekul, R. Duncan, and R. Wiwattanapatapee Effect of PEG molecular weight and linking chemistry on the biological activity and thermal stability of PEGylated trypsin Int J Pharm 357 1-2 2008 252 259
39. C. Dhalluin, A. Ross, L.A. Leuthold, and et al. Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers Bioconjug Chem 16 3 2005 504 517
40. P. Caliceti, O. Schiavon, F.M. Veronese, and I.M. Chaiken Effects of monomethoxypoly(ethylene glycol) modification of ribonuclease on antibody recognition, substrate accessibility and conformational stability J Mol Recognit 3 2 1990 89 93
41. L.S. Holm, P.W. Thulstrup, M.R. Kasimova, and M. van de Weert Preferential interactions and the effect of protein PEGylation PLoS One 10 7 2015 e0133584
42. B. Plesner, C.J. Fee, P. Westh, and A.D. Nielsen Effects of PEG size on structure, function and stability of PEGylated BSA Eur J Pharm Biopharm 79 2 2011 399 405
43. P. Stigsnaes, S. Frokjaer, S. Bjerregaard, M. van de Weert, P. Kingshott, and E.H. Moeller Characterisation and physical stability of PEGylated glucagon Int J Pharm 330 1-2 2007 89 98
44. J.A. Rodriguez-Martinez, R.J. Sola, B. Castillo, and et al. Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics Biotechnol Bioeng 101 6 2008 1142 1149
45. E.N. Baker, T.L. Blundell, J.F. Cutfield, and et al. The structure of 2Zn pig insulin crystals at 1.5 A resolution Philos Trans R Soc Lond B Biol Sci 319 1195 1988 369 456
46. M. Grace, S. Youngster, G. Gitlin, and et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b J Interferon Cytokine Res 21 12 2001 1103 1115
47. E. Girard, S. Marchal, J. Perez, and et al. Structure-function perturbation and dissociation of tetrameric urate oxidase by high hydrostatic pressure Biophys J 98 10 2010 2365 2373
48. H. Tian, Y. Guo, X. Gao, and W. Yao PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation J Pharm Pharmacol 65 1 2013 53 63
49. D. da Silva Freitas, P.J. Spencer, R.C. Vassão, and J. Abrahão-Neto Biochemical and biopharmaceutical properties of PEGylated uricase Int J Pharm 387 1-2 2010 215 222
50. B. Plesner, P. Westh, and A.D. Nielsen Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa Int J Pharm 406 1-2 2011 62 68
51. O.B. Kinstler, D.N. Brems, S.L. Lauren, A.G. Paige, J.B. Hamburger, and M.J. Treuheit Characterization and stability of N-terminally PEGylated rhG-CSF Pharm Res 13 7 1996 996 1002
52. L.S. Holm, A. McUmber, J.E. Rasmussen, and et al. The effect of protein PEGylation on physical stability in liquid formulation J Pharm Sci 103 10 2014 3043 3054
53. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, and F.F. Davis Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J Biol Chem 252 11 1977 3582 3586
54. A. Abuchowski, T. van Es, N.C. Palczuk, and F.F. Davis Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J Biol Chem 252 11 1977 3578 3581
55. A. Matsushima, H. Sasaki, Y. Kodera, and Y. Inada Reduction of immunoreactivity of bovine serum albumin conjugated with polyethylene glycol(PEG) in relation to its esterase activity Biochem Int 26 3 1992 485 490
56. H.J. Gais, and S. Ruppert Modification and immobilization of proteins with polyethylene glycol tresylates and polysaccharide tresylates: evidence suggesting a revision of the coupling mechanism and the structure of the polymer-polymer linkage Tetrahedron Lett 36 22 1995 3837 3838
57. S. Zalipsky Alkyl succinimidyl carbonates undergo Lossen rearrangement in basic buffers Chem Commun 1 1998 69 70
58. S. Zalipsky, R. Seltzer, and S. Menon-Rudolph Evaluation of a new reagent for covalent attachment of polyethylene glycol to proteins Biotechnol Appl Biochem 15 1 1992 100 114
59. A. Abuchowski, G.M. Kazo, C.R. Verhoest Jr., and et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates Cancer Biochem Biophys 7 2 1984 175 186
60. C.S. Fishburn The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics J Pharm Sci 97 10 2008 4167 4183
61. S. Li, Z. Yang, X. Sun, Y. Tan, S. Yagi, and R.M. Hoffman Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation Anal Biochem 330 2 2004 264 271
62. M.T. Davis, and J.F. Preston A simple modified carbodiimide method for conjugation of small-molecular-weight compounds to immunoglobulin G with minimal protein crosslinking Anal Biochem 116 2 1981 402 407
63. S.S. Wong Reactive groups of proteins and their modifying agents Chemistry of Protein Conjugation and Cross-Linking 1991 CRC Press Inc Boston 7 49
64. R.B. Greenwald, A. Pendri, C.D. Conover, and et al. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds J Med Chem 42 18 1999 3657 3667
65. R.B. Greenwald, K. Yang, H. Zhao, C.D. Conover, S. Lee, and D. Filpula Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery systems employing 1,6-elimination Bioconjug Chem 14 2 2003 395 403
66. S. Zalipsky, M. Qazen, J.A. Walker 2nd, N. Mullah, Y.P. Quinn, and S.K. Huang New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine Bioconjug Chem 10 5 1999 703 707
67. H. Tsubery, M. Mironchik, M. Fridkin, and Y. Shechter Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification J Biol Chem 279 37 2004 38118 38124
68. T. Peleg-Shulman, H. Tsubery, M. Mironchik, M. Fridkin, G. Schreiber, and Y. Shechter Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period J Med Chem 47 20 2004 4897 4904
69. H.R. Stennicke, M. Kjalke, D.M. Karpf, and et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models Blood 121 11 2013 2108 2116
70. J.M. Bobbitt Periodate oxidation of carbohydrates Adv Carbohydr Chem 48 11 1956 1 41
71. M. Wilchek, and E.A. Bayer Labeling glycoconjugates with hydrazide reagents Meth Enzymol 138 1987 429 442
72. E.C. Rodriguez, L.A. Marcaurelle, and C.R. Bertozzi Aminooxy-, hydrazide-, and thiosemicarbazide-functionalized saccharides: versatile reagents for glycoconjugate synthesis J Org Chem 63 21 1998 7134 7135
73. S. De Frees, Z.G. Wang, R. Xing, and et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli Glycobiology 16 9 2006 833 843
74. De Frees S, Zopf D, Bayer R, Bowe C, Hakes D, Chen X. 2007. Glycopegylation methods and proteins/peptides produced by the methods., US Pat. 7,265,085.
75. M. Sergi, F. Caboi, C. Maullu, G. Orsini, and G. Tonon Enzymatic techniques for PEGylation of biopharmaceuticals F. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Basel 75 88
76. H.R. Stennicke, H. Ostergaard, R.J. Bayer, and et al. Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives Thromb Haemost 100 5 2008 920 928
77. H. Ostergaard, J.R. Bjelke, L. Hansen, and et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide Blood 118 8 2011 2333 2341
78. M.S. Hershfield, R.H. Buckley, M.L. Greenberg, and et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase N Engl J Med 316 10 1987 589 596
79. M.S. Hershfield, N.J. Ganson, S.J. Kelly, E.L. Scarlett, D.A. Jaggers, and J.S. Sundy Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients Arthritis Res Ther 16 2 2014 R63
80. G. Pasut, M. Sergi, and F.M. Veronese Anti-cancer PEG-enzymes: 30 years old, but still a current approach Adv Drug Deliv Rev 60 1 2008 69 78
81. G. Pasut, and F.M. Veronese PEG conjugates in clinical development or use as anticancer agents: an overview Adv Drug Deliv Rev 61 13 2009 1177 1188
82. T. Maita, K. Morokuma, and G. Matsuda Amino acid sequence of L-asparaginase from Escherichia coli J Biochem 76 6 1974 1351 1354
83. S. Shifrin, B.G. Solis, and I.M. Chalken L-Asparaginase from Erwinia carotovora. Physicochemical properties of the native and succinylated enzyme J Biol Chem 248 10 1973 3464 3469
84. A. Abuchowski, T. van Es, N.C. Palczuk, J.R. McCoy, and F.F. Davis Treatment of L5178Y tumor-bearing BDF1 mice with a nonimmunogenic L-glutaminase-L-asparaginase Cancer Treat Rep 63 6 1979 1127 1132
85. M.C. Carter, and M.E. Meyerhoff Instability of succinyl ester linkages in O2'-monosuccinyl cyclic AMP-protein conjugates at neutral pH J Immunol Methods 81 2 1985 245 257
86. M.J. Keating, R. Holmes, S. Lerner, and D.H. Ho L-asparaginase and PEG asparaginase-past, present, and future Leuk Lymphoma 10 Suppl 1993 153 157
87. M.L. Graham Pegaspargase: a review of clinical studies Adv Drug Deliv Rev 55 10 2003 1293 1302
88. Y.K. Park, A. Abuchowski, S. Davis, and F. Davis Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct Anticancer Res 1 6 1981 373 376
89. M.R. Sherman, M.G. Saifer, and F. Perez-Ruiz PEG-uricase in the management of treatment-resistant gout and hyperuricemia Adv Drug Deliv Rev 60 1 2008 59 68
90. Williams LD, Hershfield MS, Kelly SJ, Saifer MGP, Sherman MR. 2003. PEG-urate oxidase conjugates and use thereof. US Pat. 6,576,235.
91. M.S. Hershfield, J.S. Sunday, N.J. Ganson, and S.J. Kelly Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout F.M. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Berlin 217 227
92. Krystexxa 2009. KRYSTEXXA TM (pegloticase) for intravenous infusion BLA No. 125293.
93. Y.S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, and D.F. Wyss Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv Drug Deliv Rev 54 4 2002 547 570
94. Y.S. Wang, S. Youngster, J. Bausch, R. Zhang, C. McNemar, and D.F. Wyss Identification of the major positional isomer of pegylated interferon alpha-2b Biochemistry 39 35 2000 10634 10640
95. D.C. Wylie, M. Voloch, S. Lee, and et al. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG Pharm Res 18 2001 1354 1360
96. D.C. Wylie, M. Voloch, S. Lee, and et al. Characterization of interferon a2B pegylated via carboxyalkylation: a case study Methods Mol Biol 308 2005 337 348
97. M.J. Grace, and D. Cutler Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway Antivir Chem Chemother 15 6 2004 287 297
98. M.J. Grace, S. Lee, S. Bradshaw, and et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway J Biol Chem 280 8 2005 6327 6336
99. K.A. Nieforth, R. Nadeau, I.H. Patel, and D. Mould Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects Clin Pharmacol Ther 59 1996 636 646
100. S.P. Monkarsh, Y. Ma, A. Aglione, and et al. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity Anal Biochem 247 2 1997 434 440
101. S.P. Monkarsh, C. Spence, J.E. Porter, and et al. Isolation of positional isomers of mono-poly(ethylene glycol)ylated interferon/α-2a and the determination of their biochemical and biological characteristics J.M. Harris, S. Zalipsky, Poly(ethylene glycol). Chemistry and Biological Applications 1997 ACS Symposium series Washington, DC 207 216
102. P.B.W. Bailon Polyethylene glycol-conjugated pharmaceutical proteins Pharm Sci Technol Today 1 1998 352 356
103. C. Monfardini, O. Schiavon, P. Caliceti, M. Morpurgo, J.M. Harris, and F.M. Veronese A branched monomethoxypoly(ethylene glycol) for protein modification Bioconjug Chem 6 1 1995 62 69
104. A. Guiotto, M. Canevari, M. Pozzobon, S. Moro, P. Orsolini, and F.M. Veronese Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation Bioorg Med Chem 12 19 2004 5031 5037
105. K. Rajender Reddy, M.W. Modi, and S. Pedder Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C Adv Drug Deliv Rev 54 4 2002 571 586
106. P. Bailon, A. Palleroni, C.A. Schaffer, and et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C Bioconjug Chem 12 2 2001 195 202
107. C. Dhalluin, A. Ross, W. Huber, and et al. Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2 Bioconjug Chem 16 3 2005 518 527
108. C. Parkinson, J.A. Scarlett, and P.J. Trainer Pegvisomant in the treatment of acromegaly Adv Drug Deliv Rev 55 10 2003 1303 1314
109. J.J. Kopchick, L. Qiu, E. Gosney, and et al. Growth Hormone Antagonists: A Pharmacological Tool in Present and Future Therapies F. Nyberg, The Somatotrophic Axis in Brain Function 2005 Academic Press Burlington 313 326
110. R.F. Finn PEGylation of human growth hormone: strategies and properties F.M. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Berlin 187 203
111. R. Clark, K. Olson, G. Fuh, and et al. Long-acting growth hormones produced by conjugation with polyethylene glycol J Biol Chem 271 36 1996 21969 21977
112. K. Olson, R. Gehant, V. Mukku, and et al. Preparation and characterization of poly (-ethylene glycol)ylated human growth hormone antagonist in poly(ethylene glycol) chemistry and biological applications 1997 ACS Symposium series. American Chemical Society Washington, DC 170 181
113. Nakamura T, Sekimori Y, Machida M, Kawata H, Miyamoto H. 2011. PEG-modified Erythropoietin. US Pat. 8,022,191.
114. M. Sherman Management of viral hepatitis: clinical and public health perspectives-a consensus statement. CASL Hepatitis Consensus Group. Canadian Association for Study of the Liver Can J Gastroenterol 11 5 1997 407 416
115. Mircera 2007. EMEA Scientific Discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Scientific-Discussion/human/000739/WC500033669.pdf. Accessed January 7, 2016.
116. TM, a novel erythropoietic receptor agonist for the treatment of anemia caused by kidney disease Blood 104:Abstract 2904; Full paper is published in Exp Hematol 2934 2006 1303 1311
117. Omontys, prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202799s000lbl.pdf. Accessed January 7, 2016.
118. J. Ruckman, L.S. Green, J. Beeson, and et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain J Biol Chem 273 32 1998 20556 20567
119. Macugen 2006. EMEA Scientific Discussion. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Scientific-Discussion/human/000620/WC500026218.pdf. Accessed January 7, 2016.
120. C.E. Tucker, L.S. Chen, M.B. Judkins, J.A. Farmer, S.C. Gill, and D.W. Drolet Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys J Chromatogr B Biomed Sci Appl 732 1 1999 203 212
121. D.W. Drolet, J. Nelson, C.E. Tucker, and et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys Pharm Res 17 12 2000 1503 1510
122. Kinstler OB, Gabriel NE, Farrar CE, DePrince RB. 1998. N-terminally chemically modified protein compositions and methods. US Pat.5,824,784.
123. Kinstler OB. 2005. N-terminally chemically modified protein compositions and methods. US Pat. 6,956,027.
124. G. Molineux The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta) Curr Pharm Des 10 11 2004 1235 1244
125. G. Molineux, O. Kinstler, B. Briddell, and et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans Exp Hematol 27 12 1999 1724 1734
126. O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, and C. Gegg Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv Drug Deliv Rev 54 4 2002 477 485
127. D.M. Piedmonte, and M.J. Treuheit Formulation of Neulasta (pegfilgrastim) Adv Drug Deliv Rev 60 1 2008 50 58
128. D.P. Baker, E.Y. Lin, K. Lin, and et al. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model Bioconjug Chem 17 1 2006 179 188
129. A.P. Chapman PEGylated antibodies and antibody fragments for improved therapy: a review Adv Drug Deliv Rev 54 4 2002 531 545
130. A.P. Chapman, P. Antoniw, M. Spitali, S. West, S. Stephens, and D.J. King Therapeutic antibody fragments with prolonged in vivo half-lives Nat Biotechnol 17 8 1999 780 783
131. A. Nesbitt, G. Fossati, M. Bergin, and et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm Bowel Dis 13 11 2007 1323 1332
132. A. Nesbitt, S. Stephens, and E. Chartash Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent F. Veronese, PEGylated Protein Drugs: Basic Science and Clinical Applications 2009 Birkhäuser Basel 229 254
133. CIMZIA 2009. EPAR Public Assessment Report. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR--Public-assessment-report/human/001037/WC500069735.pdf. Accessed January 7, 2015.
134. Athwal DS, Brown DT, Weir ANC, Popplewell AG, Chapman AP, King DJ. 2006. Biological products., US Pat. 7,012,135.
135. S. Horton, C. Walsh, and P. Emery Certolizumab pegol for the treatment of rheumatoid arthritis Expert Opin Biol Ther 12 2 2012 235 249
136. A. Baumann, D. Tuerck, S. Prabhu, L. Dickmann, and J. Sims Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis? Drug Discov Today 19 10 2014 1623 1631
137. P.L. Turecek, M.J. Bossard, M. Graninger, and et al. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation Haemostaseologie 32 Suppl 1 2012 S29 S38
138. R. Stidl, S. Fuchs, M. Bossard, J. Siekmann, P.L. Turecek, and M. Putz Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates Haemophilia 2015 Epub ahead of print